BioNotebook: Hyperion/Andromeda lead deal makers; Theravance tops public company fundraising

 
• By Mandy Jackson

Hyperion buying Andromeda; Zogenix sells Sumavel to Endo; Hydra/Boehringer collaborate; Medivation, OncoFusion partner; Theravance, Alimera raise debt; Sarepta, Agios sell stock; and Radius, Alder, Aldeyra set IPO terms.

More from Alimentary/Metabolic

More from Therapy Areas